News & Updates

Treatment with tirzepatide appears to confer reductions in blood pressure (BP) levels among individuals with obesity or overweight, with weight loss being the primary driver of this BP-lowering benefit, according to a post hoc analysis of the SURMOUNT-1 trial.

The selective Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor belumosudil mesylate appears to induce durable responses in Japanese patients with steroid-dependent/resistant chronic graft-versus-host disease (cGVHD) when used in the second or subsequent line of therapy, according to the results of a single-arm phase III study.

Implementation of a hospital-wide Alternatives to Opiates (ALTO) program falls short of reducing in-hospital or discharge opioid prescribing, reports a study.

Currently used patient education materials (PEMs) on NSAIDs are not reader-friendly for the majority of patients in Singapore, reveals a study.

Use of filgrastim among lung transplant recipients (LTRs) for the treatment of neutropenia contributes to an increased burden of acute cellular rejection (ACR) and a reduced time to ACR, but not to an increased likelihood of ACR at 6 months, a study has shown.

In preterm infants, the use of multistrain probiotics does not appear to prevent colonization with multidrug-resistant organisms or highly epidemic bacteria (MDRO+), as shown in the phase III PRIMAL* trial.

Adding olanzapine to prophylactic antiemetic medications appeared to substantially improve nausea and vomiting control among patients receiving moderately emetogenic chemotherapy (MEC) regimens in a phase III randomized clinical trial.